RE: More US sites1 Sep 2023 07:58
BV. If you recall MHRA clinical trial approval for AVA was early in’21, to be greeted with much fanfare and words like ‘transformational’ from AS, so this was already attracting much focus and will have added to any valuation around that time. The point being this Market remains highly cynical of any clinical trial until proof of concept is delivered, and as an investor the market remains the final arbiter of valve on any given day, irrespective of how you, me or anyone else feels it’s currently undervalued. The SD, that gushed with impressive data, merely proved that point and whilst we hope this delivers within a reasonable time frame, I’m not protective of the Company, nor does it take a commanding position in my portfolio.